Mineralys Therapeutics, Inc. Common Stock (MLYS) financials · $2.17B cap
Mineralys Therapeutics, Inc. Common Stock (MLYS) $2.17B cap.
| Line | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Income | -$170.6M | -$192.4M | -$84.7M |
| Net Income | -$154.7M | -$177.8M | -$71.9M |
| EPS (Diluted) | $-2.29 | $-3.66 | $-1.99 |
| Line | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Total Assets | $661.8M | $205.9M | $251.6M |
| Current Assets | $661.4M | $205.4M | $249.1M |
| Cash & Equivalents | $172.9M | $114.1M | $49.3M |
| Inventory | $0 | $0 | $0 |
| PP&E | $38.0K | $53.0K | $0 |
| Total Liabilities | $15.1M | $205.9M | $251.6M |
| Current Liabilities | $15.1M | $14.6M | $10.5M |
| Short-term Debt | $0 | $0 | $0 |
| Long-term Debt | $0 | $0 | $0 |
| Total Debt | $0 | $0 | $0 |
| Shareholders' Equity | $646.7M | $191.3M | $241.2M |
| Retained Earnings | -$457.2M | -$302.5M | -$124.7M |
| Line | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating Cash Flow | -$142.4M | -$166.3M | -$81.2M |
| CapEx | $15.0K | $96.0K | $0 |
| Investing Cash Flow | -$389.8M | $115.0M | -$160.5M |
| Financing Cash Flow | $591.0M | $116.1M | $203.2M |
| Dividends Paid | $0 | $0 | $0 |
| Net Change in Cash | $58.8M | $64.8M | -$38.4M |
| Free Cash Flow | -$142.4M | -$166.4M | -$81.2M |
FAQ
What is MLYS P/E and revenue?
Mineralys Therapeutics, Inc. Common Stock (MLYS) $2.17B cap.
What is MLYS revenue?
Mineralys Therapeutics, Inc. Common Stock last cached revenue is $0 (FY2025).
Is MLYS profitable?
Mineralys Therapeutics, Inc. Common Stock last cached net income is -$154.7M.
What are MLYS total assets?
Mineralys Therapeutics, Inc. Common Stock last cached total assets are $661.8M.
What is MLYS free cash flow?
Mineralys Therapeutics, Inc. Common Stock last cached free cash flow is -$142.4M.
Not investment advice. Cached statements, not a live tape.